1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014

  • November 2014
  • -
  • Global Markets Direct
  • -
  • 58 pages

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014’, provides an overview of the Hyperphosphatemia In Chronic Kidney Disease’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hyperphosphatemia In Chronic Kidney Disease and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Hyperphosphatemia In Chronic Kidney Disease
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Hyperphosphatemia In Chronic Kidney Disease and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Hyperphosphatemia In Chronic Kidney Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Hyperphosphatemia In Chronic Kidney Disease pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Hyperphosphatemia In Chronic Kidney Disease
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Hyperphosphatemia In Chronic Kidney Disease pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table Of Contents

Hyperphosphatemia In Chronic Kidney Disease - Pipeline Review, H2 2014
Table of Contents

Introduction 5
Global Markets Direct Report Coverage 5
Hyperphosphatemia In Chronic Kidney Disease Overview 6
Therapeutics Development 7
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Overview 7
Pipeline Products for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis 8
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics under Development by Companies 9
Hyperphosphatemia In Chronic Kidney Disease - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
Hyperphosphatemia In Chronic Kidney Disease - Products under Development by Companies 12
Hyperphosphatemia In Chronic Kidney Disease - Companies Involved in Therapeutics Development 13
Amgen Inc. 13
OPKO Health, Inc. 14
Panion and Bf Biotech Inc 15
Sanofi 16
Vifor Pharma AG 17
Hyperphosphatemia In Chronic Kidney Disease - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Target 19
Assessment by Mechanism of Action 20
Assessment by Route of Administration 22
Assessment by Molecule Type 23
Drug Profiles 25
bixalomer - Drug Profile 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Fe-SAMMS - Drug Profile 27
Product Description 27
Mechanism of Action 27
RandD Progress 27
fermagate - Drug Profile 29
Product Description 29
Mechanism of Action 29
RandD Progress 29
ferric citrate - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
RDX-002 - Drug Profile 34
Product Description 34
Mechanism of Action 34
RandD Progress 34
sucroferric oxyhydroxide - Drug Profile 35
Product Description 35
Mechanism of Action 35
RandD Progress 35
VS-501 - Drug Profile 37
Product Description 37
Mechanism of Action 37
RandD Progress 37
VS-505 - Drug Profile 38
Product Description 38
Mechanism of Action 38
RandD Progress 38
Hyperphosphatemia In Chronic Kidney Disease - Recent Pipeline Updates 39
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects 48
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products 49
Hyperphosphatemia In Chronic Kidney Disease - Product Development Milestones 50
Featured News and Press Releases 50
Oct 01, 2014: Keryx Biopharmaceuticals Announces Issuance of a New U.S. Patent for Ferric Citrate Covering Orally Administrable Forms 50
Aug 27, 2014: Velphoro receives EU marketing authorisation for treatment of hyperphosphatemia in adult CKD patients on dialysis 50
Jun 27, 2014: Velphoro recommended for approval in the European Union for the treatment of hyperphosphatemia in adult Chronic Kidney Disease patients on dialysis 51
Apr 09, 2014: Keryx Biopharmaceuticals Announces Zerenex Phase 2 Results in Non-Dialysis Dependent Chronic Kidney Disease Selected as a Late Breaking Oral Presentation at the Upcoming National Kidney Foundation 2014 Spring Clinical Meeting 51
Apr 02, 2014: Keryx Biopharmaceuticals Announces EMA Validation of Marketing Authorization Application for Zerenex 52
Mar 10, 2014: Keryx Biopharmaceuticals Announces Submission of a Marketing Authorization Application for Zerenex to the European Medicines Agency 52
Jan 17, 2014: Keryx Biopharmaceuticals Announces Marketing Approval of Ferric Citrate in Japan 53
Nov 28, 2013: Velphoro receives US FDA approval for the treatment of hyperphosphatemia in Chronic Kidney Disease Patients on dialysis 54
Oct 21, 2013: Keryx Biopharmaceuticals Announces PDUFA Goal Date for Zerenex New Drug Application 54
Oct 17, 2013: Keryx Biopharmaceuticals' Zerenex (Ferric Citrate Coordination Complex) Data Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2013 54
Appendix 57
Methodology 57
Coverage 57
Secondary Research 57
Primary Research 57
Expert Panel Validation 57
Contact Us 58
Disclaimer 58

List of Tables

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2014 7
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Early Stage Development, H2 2014 11
Products under Development by Companies, H2 2014 12
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Amgen Inc., H2 2014 13
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by OPKO Health, Inc., H2 2014 14
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Panion and Bf Biotech Inc, H2 2014 15
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Sanofi, H2 2014 16
Hyperphosphatemia In Chronic Kidney Disease - Pipeline by Vifor Pharma AG, H2 2014 17
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Target, H2 2014 19
Number of Products by Stage and Mechanism of Action, H2 2014 21
Number of Products by Stage and Route of Administration, H2 2014 22
Number of Products by Stage and Molecule Type, H2 2014 24
Hyperphosphatemia In Chronic Kidney Disease Therapeutics - Recent Pipeline Updates, H2 2014 39
Hyperphosphatemia In Chronic Kidney Disease - Dormant Projects, H2 2014 48
Hyperphosphatemia In Chronic Kidney Disease - Discontinued Products, H2 2014 49

List of Figures

Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease, H2 2014 7
Number of Products under Development for Hyperphosphatemia In Chronic Kidney Disease - Comparative Analysis, H2 2014 8
Number of Products under Development by Companies, H2 2014 9
Comparative Analysis by Late Stage Development, H2 2014 10
Comparative Analysis by Early Stage Products, H2 2014 11
Assessment by Monotherapy Products, H2 2014 18
Number of Products by Stage and Top 10 Targets, H2 2014 19
Number of Products by Top 10 Mechanism of Actions, H2 2014 20
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2014 21
Number of Products by Stage and Top 10 Routes of Administration, H2 2014 22
Number of Products by Top 10 Molecule Types, H2 2014 23
Number of Products by Stage and Top 10 Molecule Types, H2 2014 24

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

Systemic Lupus Erythematosus Market: By Therapies (Antimalarial Drugs, Non-Steroidal Anti-Inflammatory Drugs (Nsaids), Corticosteroids Cytotoxic & Immunosuppressive Drugs, Biologics, Small Molecules) & By Region (Asia-Pacific, Others)-Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Systemic lupus erythematosus, also commonly known as lupus, is an autoimmune disease which results in inflammation of tissues in the body with common symptoms like fever, fatigue, skin rashes, malaise, ...

European Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2016 - MedView

European Market Overview for Diabetes Monitoring, Treatment and Drug Delivery 2016 - MedView

  • $ 4995
  • Industry report
  • September 2016
  • by iData Research, Inc.

The European diabetes diagnosis, treatment and drug delivery market increased in 2015 and growth is expected to persist over the forecast period. Market growth will be driven by the growing prevalence ...


ref:plp2014

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.